	Application No.	Applicant(s)	
Notice of Allowability			
	09/398,522 Examin r	ISSA, JEAN-PIERRE Art Unit	
·	LXaiiiii i	Art Office	
	Jeanine A Goldberg	1634	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSI or other appropriate coloring than the color of the	ED in this application. If not included ommunication will be mailed in due course. THIS	
 This communication is responsive to 7/16/03. The allowed claim(s) is/are 10,19,21-23,33 and 37-42. The drawings filed on 15 September 1999 are accepted by Acknowledgment is made of a claim for foreign priority under the second se		(d) or (f).	
a) All b) Some* c) None of the:			
Certified copies of the priority documents have			
2. Certified copies of the priority documents have			
3. Copies of the certified copies of the priority documents of the pri	cuments have been rec	eived in this national stage application from the	
* Certified copies not received:	ndor 25 U.S.C. \$ 110/o) (to a province all application)	
5. Acknowledgment is made of a claim for domestic priority un (a) The translation of the foreign language provisional a	_ · · ·		
6. Acknowledgment is made of a claim for domestic priority up			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of			
below. Failure to timely comply will result in ABANDONMENT of 7. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which gives reas	nitted. Note the attached	d EXAMINER'S AMENDMENT or NOTICE OF	-6
8. CORRECTED DRAWINGS must be submitted. (a) including changes required by the Notice of Draftspers. 1) hereto or 2) to Paper No	son's Patent Drawing R	Review (PTO-948) attached	
(b) \square including changes required by the proposed drawing α	correction filed,	which has been approved by the Examiner.	
(c) including changes required by the attached Examiner	's Amendment / Commo	ent or in the Office action of Paper No	
Identifying indicia such as the application number (see 37 CFR 1 each sheet.	.84(c)) should be written	on the drawings in the front (not the back) of	
9. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT FOR T			
Attachment(s)			
 1☐ Notice of References Cited (PTO-892) 3☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 5☒ Information Disclosure Statements (PTO-1449), Paper No. 49 7☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material 	4∏ Inte <u>03</u> . 6⊠ Exa	cice of Informal Patent Application (PTO-152) erview Summary (PTO-413), Paper No aminer's Amendment/Comment aminer's Statement of Reasons for Allowance lier .	

REASONS FOR ALLOWANCE

1. This action is in response to the papers filed July 16, 2003. Currently, claims 10,19,21-23,33 and 37-42 are pending.

Maintained Rejections

2. The following is an examiner's statement of reasons for allowance.

Claim 10 has been amended to recite colorectal adenoma or cancer other than glioma. On page 25 and 28 of the instant specification, the specification teaches that regions 1 and 2 were frequently methylated and these 2 regions were methylated in most cancer cell types except gliomas (page 25, lines 16-18). The specification teaches sampling a large number of primary cancers including colorectal, colorectal adenomas, primary gastric cancers and AML samples. Moreover 35 cell lines from colon, lung, prostate, breast and hematopoietic tumors were analyzed. The evidence provided in the specification enables the skilled artisan to amplify either the first or second region of the CACNA1G CpG island with SEQ ID NO: 33-36 and compare and determine methylation as indicative of cancer or colorectal adenoma.

Similarly, as explained in the response, the 5, 6, and 7th regions of the CpG island of CACNA1G showed aberrant methylation in colorectal cancers, colorectal adenomas, gastric cancers and AML (page 27, lines 17-20). The evidence provided in the specification enables the skilled artisan to amplify either the 5th, 6th or 7th region of the CACNA1G CpG island with SEQ ID NO: 41-45 and compare and determine methylation as indicative of colorectal cancers, colorectal adenomas, gastric cancers and AML.

Application/Control Number: 09/398,522 Page 3

Art Unit: 1634

3. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on

Statement of Reasons for Allowance."

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jeanine Goldberg whose telephone number is (703) 306-5817. The examiner can normally be reached Monday-Friday from 6:00 a.m. to 3:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax number for this Group is (703) 305- 3014.

Any inquiry of a general nature should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Jeanine Goldberg Patent Examiner October 7, 2003

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600